secwatch.observer — SEC 8-K summary
======================================

Issuer:     Disc Medicine, Inc. (IRON)
CIK:        0001816736
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001193125-24-134796
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Disc Medicine Q1 net loss $26.9M; bitopertin AURORA trial misses primary endpoint, but shows secondary benefits
--------------------------------------------------------------------------------

- Cash and cash equivalents $342.6M at March 31, 2024; provides runway well into 2026.
- Net loss $26.9M in Q1 2024 vs. $22.8M in Q1 2023; R&D expense rose to $23.7M from $20.2M.
- Bitopertin AURORA phase 2 in EPP: significant PPIX reduction; missed primary endpoint (light tolerance) due to placebo benefit; 60mg dose showed significant reduction in phototoxic pain reactions.
- Received FDA Rare Pediatric Disease Designation for bitopertin in EPP in May 2024.
- On track to present additional AURORA/BEACON data, initial DISC-3405 SAD data, and updated DISC-0974 MF data in Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1816736/000119312524134796/0001193125-24-134796-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1816736/000119312524134796/d827802d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-134796

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer